 Neuroblastoma
"Neuroblastoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)
| Descriptor ID |
D009447
|
| MeSH Number(s) |
C04.557.465.625.600.590.650.550 C04.557.470.670.590.650.550 C04.557.580.625.600.590.650.550
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neuroblastoma".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Neoplasms, Germ Cell and Embryonal [C04.557.465]
- Neuroectodermal Tumors [C04.557.465.625]
- Neoplasms, Neuroepithelial [C04.557.465.625.600]
- Neuroectodermal Tumors, Primitive [C04.557.465.625.600.590]
- Neuroectodermal Tumors, Primitive, Peripheral [C04.557.465.625.600.590.650]
- Neuroblastoma [C04.557.465.625.600.590.650.550]
- Neoplasms, Glandular and Epithelial [C04.557.470]
- Neoplasms, Neuroepithelial [C04.557.470.670]
- Neuroectodermal Tumors, Primitive [C04.557.470.670.590]
- Neuroectodermal Tumors, Primitive, Peripheral [C04.557.470.670.590.650]
- Neuroblastoma [C04.557.470.670.590.650.550]
- Neoplasms, Nerve Tissue [C04.557.580]
- Neuroectodermal Tumors [C04.557.580.625]
- Neoplasms, Neuroepithelial [C04.557.580.625.600]
- Neuroectodermal Tumors, Primitive [C04.557.580.625.600.590]
- Neuroectodermal Tumors, Primitive, Peripheral [C04.557.580.625.600.590.650]
- Neuroblastoma [C04.557.580.625.600.590.650.550]
Below are MeSH descriptors whose meaning is more specific than "Neuroblastoma".
This graph shows the total number of publications written about "Neuroblastoma" by people in this website by year, and whether "Neuroblastoma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 2 | 3 | | 1994 | 1 | 0 | 1 | | 1995 | 2 | 1 | 3 | | 1996 | 4 | 3 | 7 | | 1998 | 1 | 1 | 2 | | 1999 | 0 | 3 | 3 | | 2000 | 1 | 1 | 2 | | 2001 | 2 | 1 | 3 | | 2003 | 1 | 2 | 3 | | 2004 | 1 | 0 | 1 | | 2005 | 2 | 1 | 3 | | 2006 | 6 | 3 | 9 | | 2007 | 6 | 2 | 8 | | 2008 | 4 | 1 | 5 | | 2009 | 5 | 1 | 6 | | 2010 | 4 | 0 | 4 | | 2011 | 2 | 0 | 2 | | 2012 | 1 | 3 | 4 | | 2013 | 2 | 2 | 4 | | 2014 | 1 | 1 | 2 | | 2015 | 2 | 0 | 2 | | 2016 | 1 | 1 | 2 | | 2017 | 6 | 2 | 8 | | 2018 | 3 | 3 | 6 | | 2019 | 1 | 0 | 1 | | 2020 | 3 | 0 | 3 | | 2021 | 4 | 0 | 4 | | 2022 | 4 | 0 | 4 | | 2023 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Neuroblastoma" by people in Profiles.
-
Zhou W, Graner M, Paucek P, Beseler C, Boisen M, Bubak A, Asturias F, George W, Graner A, Ormond D, Vollmer T, Alvarez E, Yu X. Multiple sclerosis plasma IgG aggregates induce complement-dependent neuronal apoptosis. Cell Death Dis. 2023 04 08; 14(4):254.
-
Lerman BJ, Li Y, Carlowicz C, Granger M, Cash T, Sadanand A, Somers K, Ranavaya A, Weiss BD, Choe M, Foster JH, Pinto N, Morgenstern DA, Rafael MS, Streby KA, Zeno RN, Mody R, Yazdani S, Desai AV, Macy ME, Shusterman S, Federico SM, Bagatell R. Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor. J Clin Oncol. 2023 01 20; 41(3):508-516.
-
Park JR, Villablanca JG, Hero B, Kushner BH, Wheatley K, Beiske KH, Ladenstein RL, Baruchel S, Macy ME, Moreno L, Seibel NL, Pearson AD, Matthay KK, Valteau-Couanet D. Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. Cancer. 2022 Nov 01; 128(21):3775-3783.
-
DuBois SG, Macy ME, Henderson TO. High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-13.
-
Leibowitz MS, Zelley K, Adams D, Brodeur GM, Fox E, Li MM, Mattei P, Pogoriler J, MacFarland SP. Neuroblastoma and cutaneous angiosarcoma in a child with PTEN hamartoma tumor syndrome. Pediatr Blood Cancer. 2022 10; 69(10):e29656.
-
Slatnick LR, Jimeno A, Gore L, Macy ME. Naxitamab: a humanized anti-glycolipid disialoganglioside (anti-GD2) monoclonal antibody for treatment of neuroblastoma. Drugs Today (Barc). 2021 Nov; 57(11):677-688.
-
Rozen EJ, Shohet JM. Systematic review of the receptor tyrosine kinase superfamily in neuroblastoma pathophysiology. Cancer Metastasis Rev. 2022 03; 41(1):33-52.
-
Bates PD, Rakhmilevich AL, Cho MM, Bouchlaka MN, Rao SL, Hales JM, Orentas RJ, Fry TJ, Gilles SD, Sondel PM, Capitini CM. Combining Immunocytokine and Ex Vivo Activated NK Cells as a Platform for Enhancing Graft-Versus-Tumor Effects Against GD2+ Murine Neuroblastoma. Front Immunol. 2021; 12:668307.
-
Weiss BD, Yanik G, Naranjo A, Zhang FF, Fitzgerald W, Shulkin BL, Parisi MT, Russell H, Grupp S, Pater L, Mattei P, Mosse Y, Lai HA, Jarzembowski JA, Shimada H, Villablanca JG, Giller R, Bagatell R, Park JR, Matthay KK. A safety and feasibility trial of 131 I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study. Pediatr Blood Cancer. 2021 10; 68(10):e29117.
-
Li Z, Wang-Heaton H, Cartwright BM, Makinwa Y, Hilton BA, Musich PR, Shkriabai N, Kvaratskhelia M, Guan S, Chen Q, Yu X, Zou Y. ATR prevents Ca2+ overload-induced necrotic cell death through phosphorylation-mediated inactivation of PARP1 without DNA damage signaling. FASEB J. 2021 05; 35(5):e21373.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|